Ivim's low entry price gets bigger once the membership is added. Its individualized, titrated dosing model with provider guidance is a genuine clinical strength. But the required $75/mo membership (first month free), separate from the medication, raises the true monthly cost above the advertised medication price, compound programs require upfront payment, and it does not clearly name its current compounding pharmacy.
Ivim Health at a glance
- Category:
- Telehealth weight-loss (GLP-1)
- Medication:
- Compounded semaglutide & tirzepatide (not FDA-approved)
- Semaglutide:
- From ~$75/mo (12-mo); ~$100/mo (6-mo) — plus membership
- Tirzepatide:
- From ~$133/mo (12-mo); ~$183/mo (6-mo) — plus membership
- Membership fee:
- $75/mo (first month free), required & separate from medication
- Payment:
- Compound programs require upfront payment
- Pharmacy:
- Not clearly named (verify)
- Rating:
- Rating pending verification
- Clinical model:
- Individualized / titrated dosing with provider oversight
- Regulatory note:
- None identified (Jun 2026; verify)
Pros and cons
What we like
- Low medication entry price
- Individualized, titrated dosing model
- Provider guidance through the program
- Free initial consult
Trade-offs to know
- Required $75/mo membership (first month free), separate from medication, raises the true cost
- Upfront payment required for compound programs
- Does not clearly name its compounding pharmacy
- Smaller review base than incumbents
- Medication is compounded — not FDA-approved
Scorecard
Scored on the same five-criterion rubric we apply to every provider. Weights in parentheses.
Pricing: low entry, required membership
Ivim advertises a low medication entry price on a 12-month plan — compounded semaglutide from about $75/mo and compounded tirzepatide from about $133/mo (roughly $100/mo and $183/mo on a 6-month plan). But it also requires a $75/mo membership (first month free), separate from and required alongside the medication for the plan's duration, so the true monthly cost lands well above the sticker price. Compound programs also require upfront payment. If you want the lowest medication entry number and value titrated dosing, Ivim is competitive; if you want a single predictable all-in figure, the membership makes budgeting harder. Verify current pricing on ivimhealth.com.
Pharmacy & sourcing
Ivim does not clearly name its current compounding pharmacy in its public materials. Because compounded drugs are not FDA-approved, an undisclosed pharmacy removes a key way for patients to verify sourcing and request a certificate of analysis. This is the main reason Ivim scores lower on pharmacy disclosure than its clinical model alone would suggest. Verify current sourcing details directly with Ivim.
Reviews & reputation
We have not verified Ivim's third-party rating to a primary source, so we show its rating as pending verification rather than publish an unconfirmed number. Ivim has a smaller review base than the national incumbents, so individual reviews carry more weight — read recent ones and check current listings. Reported feedback spans both the clinical experience and billing; confirm details before deciding.
Clinical model
Ivim's differentiator is an individualized, titrated dosing model with provider oversight — dosing is adjusted to the patient rather than sold as a fixed monthly package. That's a real clinical strength and the criterion where Ivim scores highest. As with any GLP-1 program, a licensed clinician determines whether treatment is appropriate; medication is not guaranteed and individual results vary.
Regulatory context
As of June 2026, we identified no manufacturer lawsuit or FDA warning letter naming Ivim. Regulatory posture is part of our rubric, so we note this factually rather than as an endorsement. Verify current status against the live FDA warning-letter database and public court dockets before deciding.
Who Ivim is best for
Choose Ivim if you want a low medication entry price with individualized, titrated dosing and don't mind a monthly membership. Consider our #1 pick instead if you want one flat all-in price with no membership and a provider that names its pharmacy — see our MaxLife review.
Ivim Health FAQ
How much does Ivim Health really cost?
Ivim advertises a low medication entry price on a 12-month plan — compounded semaglutide from about $75/mo and compounded tirzepatide from about $133/mo (roughly $100 and $183/mo on a 6-month plan) — but it also requires a $75/mo membership (first month free), separate from and required alongside the medication. The membership runs for the plan's duration and compound programs require upfront payment, so the true monthly cost is higher than the entry price. Verify current pricing on ivimhealth.com.
Does Ivim Health name its compounding pharmacy?
Not clearly. Ivim does not clearly name its current compounding pharmacy in its public materials. Because compounded drugs are not FDA-approved, an undisclosed pharmacy removes a key way to verify sourcing. Verify current sourcing details with Ivim.
Is Ivim Health FDA-approved?
Ivim's compounded semaglutide and tirzepatide are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Compounded semaglutide is not Ozempic® or Wegovy®; compounded tirzepatide is not Mounjaro® or Zepbound®.